Cost-effectiveness of post-exposure prophylaxis following sexual exposure to HIV

AIDS

Volumn 12, Issue 9, 1998, Pages 1067-1078

  Pinkerton, Steven D ^a   Holtgrave, David R ^a   Bloom, Frederick R ^a  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

Author keywords

Cost effectiveness analysis; HIV; Post exposure prophylaxis; Sexual transmission

Indexed keywords

INDINAVIR; LAMIVUDINE; ZIDOVUDINE;

ARTICLE; CHEMOPROPHYLAXIS; COST EFFECTIVENESS ANALYSIS; FEMALE; HEALTH CARE COST; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION PREVENTION; INFECTION RISK; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; SEXUAL INTERCOURSE; SEXUALLY TRANSMITTED DISEASE; TREATMENT OUTCOME;

EID: 0032543633     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-199809000-00015     Document Type: Article

References (50)

1. Centers for Disease Control. Update: provisional Public Health Service recommendations for chemoprophylaxis after occupational exposure to HIV. MMWR 1996, 45:468-472.
2. Centers for Disease Control: Case-control study of HIV seroconversion in health-care workers after percutaneous exposure to HIV-infected blood - France, United Kingdom, and United States, January 1988-August 1994. MMWR 1995, 44:929-933.
3. Carpenter CCJ, Fischl MA, Hammer SM, et al.: Antiretroviral therapy for HIV infection in 1996: recommendations of an international panel. JAMA 1996, 276:146-154.
4. American Health Consultants: CDC: avoid preventive therapy for sexual risk. AIDS Alert 1996, 11:75-76.
5. Gerberding JL: Prophylaxis for occupational exposure to HIV. Ann Intern Med 1996, 125:497-501.
6. Macready N: Investigators study morning-after AIDS treatment [news]. Lancet 1997, 349:780.
7. Gostin LO, Lazzarini Z, Alexander D, Brandt AM, Mayer KH, Silverman DC: HIV testing, counseling, and prophylaxis after sexual assault. JAMA 1994, 271:1436-1444.
8. Katz MH, Gerberding JL: Postexposure treatment of people exposed to the human immunodeficiency virus through sexual contact or injection-drug use. N Engl J Med 1997, 336:1098-1100.
9. Centers for Disease Control: Public Health Service statement on management of occupational exposure to human immunodeficiency virus, including considerations regarding postexposure use. MMWR 1990, 39 (RR-1):1-14.
10. Mathes LF, Polas PJ, Hayes KA, Swenson CL, Johnson S, Kociba GJ: Pre- and postexposure chemoprophylaxis: evidence that 3′-azido-3′-dideoxythymidine inhibits feline leukemia virus disease by a drug-induced vaccine response. Antimicrob Agents Chemother 1992, 36:2715-2721.
11. Marlin LN, Murphey-Corb M, Soike KF, Davison-Fairburn B, Baskin GB: Effects of initiation of 3′-azido-3′-dideoxythymidine (zidovudine) treatment at different times after infection of rhesus monkeys with simian immunodeficiency virus. J Infect Dis 1993, 168:825-835.
12. Gorman C: If the condom breaks. Time 1997, 23 June.
13. Zuger A: 'Morning after' treatment for AIDS. New York Times 1997, 10 June.
14. Holtgrave DR: Cost analysis and HIV prevention programs. Am Psychol 1994, 49:1088-1089.
15. Holtgrave DR, Qualls NL, Graham JD: Economic evaluation of HIV prevention programs. Annu Rev Public Health 1996, 17:467-488.
16. Pinkerton SD, Holtgrave DR, Pinkerton HJ: Cost-effectiveness of chemoprophylaxis after occupational exposure to HIV. Arch Intern Med 1997, 157:1972-1980.
17. Pinkerton SD, Holtgrave DR, Bloom FR. Postexposure treatment of HIV. N Engl J Med 1997, 337:500-501.
18. Drummond MF, Stoddart GL, Torrance GW: Methods for the Economic Evaluation of Health Care Programmes. New York: Oxford University Press: 1987.
19. Haddix AC, Teutsch SM, Shaffer PA, Duñet DO (Eds): Prevention Effectiveness: A Guide to Decision Analysis and Economic Evaluation. New York: Oxford University Press; 1996.
20. Weinstein MC, Stason WB: Foundations of cost-effectiveness analysis for health and medical practices. N Engl J Med 1977, 296:716-721.
21. Cold MR, Siegel JE, Russell LB, Weinstein MC (Eds): Cost-Effectiveness in Health and Medicine. New York: Oxford University Press; 1996.
22. Pinkerton SD, Holtgrave DR: Assessing the cost-effectiveness of HIV prevention interventions: a primer. In Handbook of Economic Evaluation of HIV Prevention Programs. Edited by Holtgrave DR. New York: Plenum Press; 1998 (in press).
23. Pinkerton SD, Holtgrave DR: A method for evaluating the economic efficiency of HIV behavioral risk reduction interventions. AIDS Behav 1998 (in press).
24. Ganiats TG, Wong AF: Evaluation of cost-effectiveness research: a survey of recent publications. Fam Med 1991, 23:457-462.
25. Laupacis A, Feeny D, Detsky AS, Tugwell PX: Tentative guidelines for using clinical and economic evaluations revisited. Can Med Assoc J 1993, 148:927-929.
26. Fabian R: The Qualy approach. In Valuing Health for Policy: An Economic Approach. Edited by Tolley GL, Kenkel D, Fabian R. Chicago: University of Chicago Press; 1994:118-136.
27. Pinkerton SD, Abramson PR: The Bernoulli-process model of HIV transmission: applications and implications. In Handbook of Economic Evaluation of HIV Prevention Programs. Edited by Holtgrave DR. New York: Plenum Press; 1998 (in press).
28. Pinkerton SD, Abramson PR: Evaluating the risks: a Bernoulli process model of HIV infection and risk reduction. Eval Rev 1993, 17:504-528.
29. Holmberg SD: The estimated prevalence and incidence of HIV in 96 large US metropolitan areas. Am J Public Health 1996, 86:642-654.
30. Mastro TD, de Vincenzi I: Probabilities of sexual HIV-1 transmission. AIDS 1996, 10 (suppl A):S75-S82.
31. Royce RA, Seña A, Cates Jr W, Cohen MS: Sexual transmission of HIV. N Engl J Med 1997, 336:1072-1078.
32. Tokars JI, Marcus R, Culver DH, et al.: Surveillance of HIV infection and zidovudine use among health care workers after occupational exposure to HIV-infected blood. Ann Intern Med 1993, 118:913-919.
33. Henderson DK: Postexposure chemoprophylaxis for occupational exposure to human immunodeficiency virus type 1: current status and prospects for the future. Am J Med 1991, 91:322S-329S.
34. Puro V, Ippolito G, Guzzanti E, et al.: Zidovudine prophylaxis after accidental exposure to HIV: the Italian experience. AIDS 1992, 6:963-969.
35. Schmitz SH, Scheding S, Voliotis D, Rasokat H, Diehl V, Schrappe M: Side-effects of AZT prophylaxis after occupational exposure to HIV-infected blood. Ann Hematol 1994, 69:135-138.
36. van Leeuwen R, Katlama C, Kitchen V, et al.: Evaluation of safety and efficacy of 3TC (Iamivudine) in patients with asymptomatic or mildly symptomatic human immunodeficiency virus infection: a phase I/II study. J Infect Dis 1995, 171:1166-1171.
37. Deeks SG, Smith M, Holodniy M, Kahn JO: HIV-1 protease inhibitors: a review for clinicians. JAMA 1997, 277:145-153.
38. Holtgrave DR, Pinkerton SD: Updates of cost of illness and quality of life estimates for use in economic evaluations of HIV prevention programs. J Acquir Immune Defic Syndr Hum Retrovirol 1997, 16:54-62.
39. Gable CB, Tierce JC, Simison D, Ward D, Motte K: Costs of HIV+/AIDS at CD4+ counts disease stages based on treatment protocols. J Acquir Immune Defic Syndr Hum Retrovirol 1996, 12:413-420.
40. Guinan ME, Farnham PG, Holtgrave DR: Estimating the value of preventing a human immunodeficiency virus infection. Am J Prev Med 1994, 10:1-4.
41. Hellinger FJ: The lifetime cost of treating a person with HIV. JAMA 1993, 270:474-470.
42. Hurley SF, Kaldor JM, Gardiner S, Carlin JB, Assunção RM, Evans DB: Lifetime cost of human immunodeficiency virus-related health care. J Acquir Immune Defit Syndr Hum Retrovirol 1996, 12:371-378.
43. Pinkerton SD, Holtgrave DR: Lifetime costs of HIV/AIDS medical care [letter]. J Acquir Immune Defic Syndr Hum Retrovirol 1997, 14:380-381.
44. Editorial: New drugs for HIV infection. Med Lett Drugs Ther 1996, 38:35-37.
45. Li WR, Wong JB: Postexposure treatment of HIV. N Engl J Med 1997, 337:499-500.
46. Black RJ: Animal models of prophylaxis. Am J Med 1997, 102 (suppl 5B):S39-S44.
47. Gerberding JL: Management of occupational exposures to blood-borne viruses. N Engl J Med 1995, 332:444-451.
48. Holtgrave DR, Pinkerton SD: The cost-effectiveness of small group and community-level interventions. In Handbook of Economic Evaluation of HIV Prevention Programs. Edited by Holtgrave DR. New York: Plenum Press; 1998 (in press).
49. Holtgrave DR, Pinkerton SD: The economics of HIV primary prevention. In Handbook of HIV Prevention. Edited by Peterson JL, DiClemente RJ. New York: Plenum Press; 1998 (in press).
50. Brandt AM: No Magic Bullet: A Social History of Venereal Disease in the United States. Oxford: Oxford University Press; 1985.